BDMD vs LGVN

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 3/9, indicating poor financial health. Despite a seemingly reasonable Price/Book of 0.77 and a strong Gross Margin of 86.94%, the company is deeply unprofitable with negative operating and net margins, collapsing revenue, and no analyst coverage. The complete absence of Altman Z-Score and intrinsic value calculations, combined with a 5-year return of -89.3%, signals severe distress. Technical indicators and insider sentiment are also weak, reinforcing a high-risk outlook.

LGVN exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in nearly all fundamental health categories. The company suffers from extreme operating losses (-1479.18% margin) and negative revenue growth (-39.50% YoY), suggesting a failing business model or a high-risk clinical stage. While the current ratio of 1.33 provides a temporary liquidity cushion and analyst targets are aggressively optimistic, the deterministic data points to a high probability of further capital erosion.